SecBot SecBot
PRESS-RELEASE ·Filed Jun 12, 2026

LYEL

Lyell Immunopharma, Inc
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is an interim data update with no new efficacy or regulatory decision, limited near-term trading catalyst. The next meaningful binary event is the PiNACLE data update in H2 2026. Current safety and translational data directionally positive but well within expectations for a CAR T therapy; no reason to reposition ahead of pivotal readout.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.50
T+0 close · Jun 12, 2026 · via day close
Latest settled
+0.22%
T+60 · $13.53
Vs SPY
−3.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $13.50entry
  2. T+1 · 5mo ago +0.37%α −1.39% · $13.55
  3. T+5 · 5mo ago −5.63%α −6.30% · $12.74
  4. T+20 · 4mo ago +11.19%α +9.41% · $15.01
  5. T+60 · 2mo ago +0.22%α −3.04% · $13.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lyell Immunopharma presented updated Phase 1/2 safety and translational data for its CAR T-cell therapy ronde-cel at EHA 2026, including a 97% manufacturing success rate and no Grade ≥3 CRS in 108 patients with R/R LBCL, supporting potential for outpatient administration and durably differentiated responses. However, this is an interim data readout, not a pivotal regulatory event; the key catalyst is the PiNACLE trial data update expected H2 2026, with pivotal data and BLA submission not expected until mid-2027 and H2 2027, respectively.

Key Facts

  • 108 patients with R/R LBCL treated with ronde-cel; 97% manufacturing success rate
  • No Grade ≥3 CRS across 108 patients; Grade ≥3 ICANS in 8% (prophylaxis) vs 16% (no prophylaxis)
  • Translational data: Cytotoxic T cells with Memory Potential (Tcmp) more abundant in durable responders (>12 months) vs progressive disease
  • Durable complete responses >12 months observed even in patients with low CD19/CD20 antigen expression
  • PiNACLE pivotal trial data update expected H2 2026; pivotal data mid-2027 with BLA submission H2 2027

Financial Impact

Pre-revenue clinical-stage biotech with $320M market cap; no financial data disclosed. Event is a data presentation, not a value-changing catalyst. Stock may see modest movement on perceived safety differentiation, but not transformative until pivotal data.

Risk Factors

  • Clinical-stage biotech with no approved products; stock is pre-revenue and highly binary on trial outcomes
  • PiNACLE data delay or negative efficacy/safety result would significantly impair valuation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311241

Track record

21 reports on LYEL

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
  2. Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
  7. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
  9. Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
  10. Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026